Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Taysha Gene Therapies and Whitehawk Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
Earnings & Valuation
This table compares Taysha Gene Therapies and Whitehawk Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Taysha Gene Therapies | $5.49 million | 282.47 | -$109.00 million | ($0.42) | -11.32 |
| Whitehawk Therapeutics | $7.14 million | 30.30 | -$20.60 million | ($1.12) | -3.39 |
Whitehawk Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Institutional & Insider Ownership
77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for Taysha Gene Therapies and Whitehawk Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Taysha Gene Therapies | 1 | 0 | 12 | 2 | 3.00 |
| Whitehawk Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
Taysha Gene Therapies currently has a consensus target price of $12.77, suggesting a potential upside of 168.54%. Whitehawk Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 116.07%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Whitehawk Therapeutics.
Summary
Taysha Gene Therapies beats Whitehawk Therapeutics on 9 of the 14 factors compared between the two stocks.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
